LIfT BioSciences

LIfT BioSciences is a preclinical-stage company dedicated to the first-in-human trial of our first-generation ATMP, the N-LIfT platform, which represents neutrophil-based leukocyte infusion therapy. The product is made from myeloid progenitor cells committed to immunomodulatory α-neutrophils (IMAN), manufactured in vitro from healthy donor HSPCs, with superior innate cancer-killing ability.